Recent studies have converged on the overlap of GLP|GIP|GCGR agonist therapies and DA signaling. While GIP stimulators are commonly employed for managing type 2 diabetes, their potential consequences on reinforcement https://hamzahnegl705862.onesmablog.com/novel-gip-agonists-and-dopamine-adjustment-a-comparative-copyrightination-82801778